千金藥業(600479.SH):公司外部董事袁斌接受紀律審查和監察調查
格隆匯3月15日丨千金藥業(600479.SH)公佈,公司於2022年3月15日通過清廉株洲網站獲悉,株洲市國有資產投資控股集團有限公司(“株洲國投集團”)黨委委員、副總經理、公司外部董事袁斌涉嫌嚴重違紀違法,目前正接受株洲市紀委監委紀律審查和監察調查。株洲國投集團作為公司控股股東僅通過依法行使股東權利、履行股東義務參與公司治理,不直接參與公司經營管理工作。公司資產完整,人員、財務、機構和業務等方面均獨立運營,公司及下屬企業的業務經營活動均正常有序開展。
鑑於上述原因,公司外部董事袁斌無法正常履行職責,其違紀違法行為不會對公司經營管理活動產生重大影響。該事項不會導致公司董事人數低於法定最低人數,不影響公司董事會的正常運作。公司將依據《公司法》、《公司章程》等有關規定儘快補選新任董事,並將根據相關事宜進展情況及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.